Beigene, Ltd. (NASDAQ:ONC - Get Free Report) insider Titus B. Ball sold 134 shares of the stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $258.36, for a total value of $34,620.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Beigene Stock Performance
Shares of ONC stock traded down $6.71 during trading hours on Friday, hitting $269.82. 306,851 shares of the company were exchanged, compared to its average volume of 450,214. The stock has a market capitalization of $31.94 billion, a price-to-earnings ratio of -32.75, a P/E/G ratio of 7.73 and a beta of 0.30. The company's 50 day simple moving average is $240.18. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. Beigene, Ltd. has a fifty-two week low of $141.31 and a fifty-two week high of $287.88.
Beigene (NASDAQ:ONC - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $1.93. The firm had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.12 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. As a group, sell-side analysts expect that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.
Wall Street Analyst Weigh In
ONC has been the topic of a number of analyst reports. JMP Securities set a $348.00 price objective on shares of Beigene in a report on Friday, February 28th. JPMorgan Chase & Co. lifted their target price on shares of Beigene from $311.00 to $317.00 and gave the stock an "overweight" rating in a report on Monday, April 21st. Bank of America upgraded shares of Beigene from a "neutral" rating to a "buy" rating and increased their price objective for the company from $207.00 to $320.00 in a research note on Monday, March 3rd. Royal Bank of Canada reduced their target price on shares of Beigene from $312.00 to $311.00 and set an "outperform" rating on the stock in a research report on Thursday, May 8th. Finally, TD Securities reissued a "buy" rating and issued a $334.00 target price on shares of Beigene in a research note on Thursday, April 24th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Beigene presently has an average rating of "Buy" and a consensus target price of $319.00.
Read Our Latest Analysis on ONC
About Beigene
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Recommended Stories
Before you consider Beigene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beigene wasn't on the list.
While Beigene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
